Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31338827 | 0.97 | — | — | |
| SCHEMBL2385655 | 0.97 | — | — | |
| SCHEMBL2387799 | 0.94 | — | — | |
| SCHEMBL27343034 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL1115730 | 0.90 | — | — | |
| SCHEMBL353008 | 0.87 | — | — | |
| SCHEMBL28799076 | 0.86 | EPHX1 (0.70) | — | |
| SCHEMBL27894435 | 0.84 | EPHX1 (0.75) | — | |
| SCHEMBL27877609 | 0.84 | EPHX1 (0.75) | — | |
| Hydrochloric Acid SCHEMBL29875090 | 0.83 | EPHX1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105121418-A | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection | GILEAD SCIENCES INC | 2015-12-02 | — | — | CN | disclosed |
| CN-102503959-B | Tricyclic compounds and preparation method thereof, and medicinal composition containing compounds and application thereof | UNIV SOUTHERN MEDICAL | 2015-04-08 | — | — | CN | disclosed |
| CN-102516263-B | Spirotricyclic compound, its preparation method, and pharmaceutical composition containing it as well as application thereof | UNIV SOUTHERN MEDICAL | 2015-04-08 | — | — | CN | disclosed |
| CN-102325752-B | Carbazole and carboline kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2015-02-04 | — | — | CN | disclosed |
| CN-103221047-B | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2014-12-17 | — | — | CN | disclosed |
| CN-102325753-B | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2014-09-10 | — | — | CN | disclosed |
| US-8772268-B2 | Bisphosphonamidate prodrugs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130090311-A1 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| CN-101160314-B | Small molecule inhibitors of MDM2 and uses thereof | UNIV MICHIGAN | 2012-05-23 | — | — | CN | disclosed |
| WO-2011139791-A2 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7173020-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1268493-B1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050171060-A1 | Phosphoramidates and methods therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-04 | — | — | US | disclosed |
| US-6903081-B2 | Phosphoramidates and methods therefor | PURDUE RESEARCH FOUNDATION (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1268493-A1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020004594-A1 | Phosphoramidates and methods therefor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-01-10 | — | — | US | disclosed |
| WO-2001074827-A1 | PHOSPHORAMIDATE PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2001-10-11 | — | — | WO | disclosed |